Royalty Pharma RPRX
NASDAQ RPRX
$69.31 +0.34 (+0.49%)
At close: Nov 13, 2026 · 4:00 PM EST

Royalty Pharma (RPRX) Investment Gain (Loss) (2020 - 2021)

Updated

Royalty Pharma (RPRX) reported Investment Gain (Loss) of $154.91 million for FY2024, down 32.9% from $230.84 million in FY2023.

Analysis

Royalty Pharma (RPRX) Investment Gain (Loss) (2020 - 2021) Analysis & Trends

Dating back to FY2018, Royalty Pharma's Investment Gain (Loss) record includes 7 years.

  • Investment Gain (Loss) has a five-year compound annual growth rate of 90.6% (FY2019 to FY2024).
  • Five-year annual Investment Gain (Loss) spans a low of -$6.82 million in FY2022 and a high of $230.84 million in FY2023.
  • According to Business Quant data, Investment Gain (Loss) came in at $230.84 million in FY2023, -$6.82 million in FY2022, $17.86 million in FY2021 (-4.0%) and $18.6 million in FY2020 (+202.0%).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Investment Gain (Loss) (Qtr)
1 Royalty Pharma 39.80 Bn 40.13 Bn - -
2 Rocket Companies 38.90 Bn 27.72 Bn - -
3 Orix 38.66 Bn 9.30 Bn 13.83 Bn -
4 Federal National Mortgage Association Fannie Mae 26.46 Bn -16,107.65 Bn - -
5 Synchrony Financial 22.47 Bn -45.15 Bn - -
6 Affirm Holdings 22.07 Bn 15.11 Bn - -
7 Royal Gold 21.71 Bn 20.92 Bn 402.46 Mn -15.66 Mn
8 Ares Capital 13.84 Bn 11.59 Bn - -66.50 Mn
9 Annaly Capital Management 13.83 Bn 4.86 Bn - -27.34 Mn
10 Federal Home Loan Mortgage 12.64 Bn -328.33 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 6.03 Mn
Mar 31, 2021 5.13 Mn
Jun 30, 2020 6.95 Mn
Mar 31, 2020 52.73 Mn
API Access

Royalty Pharma Investment Gain (Loss) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=investment-gain-loss&ticker=RPRX&period=max&api_key=YOUR_API_KEY